A similar observation was made in mouse Duchenne muscular dystrophy upon AAV-based gene therapy treatment, when an antisense oligonucleotides pre-treatment that allowed transient expression of dystrophin at the sarcolemma of myofibers improved their condition and limited AAV genome loss after vector administration, eventually resulting in a long-term therapeutic effect [29]. Here, DMD is linked to Duchenne muscular dystrophy.